ABSTRACT
Objective
To analyze the legal demands of tiotropium bromide to treat chronic obstructive pulmonary disease.
Methods
We included secondary data from the pharmaceutical care management systems made available by the Paraná State Drug Center.
Results
Public interest civil action and ordinary procedures, among others, were the most common used by the patients to obtain the medicine. Two Health Centers in Paraná (Londrina and Umuarama) concentrated more than 50% of the actions. The most common specialty of physicians who prescribed (33.8%) was pulmonology. There is a small financial impact of tiotropium bromide on general costs with medicines of the Paraná State Drug Center. However, a significant individual financial impact was observed because one unit of the medicine represents 38% of the Brazilian minimum wage.
Conclusion
Our study highlights the need of incorporating this medicine in the class of long-acting anticholinergic bronchodilator in the Brazilian public health system.
Judicial decisions; Pulmonary disease, chronic obstructive; Tiotropium bromide; Unified Health System; Pharmaceutical Services
